Armstrong Advisory Group’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$298K Buy
10,442
+42
+0.4% +$1.12K 0.02% 196
2026
Q2
$250K Buy
10,400
+40
+0.4% +$1.05K 0.02% 220
2026
Q1
$291K Sell
10,360
-124
-1% -$3.3K 0.02% 195
2025
Q4
$261K Buy
10,484
+3,328
+47% +$83.9K 0.02% 196
2025
Q3
$182K Sell
7,156
-1,764
-20% -$43.5K 0.01% 227
2025
Q2
$216K Buy
8,920
+2,895
+48% +$67.5K 0.02% 199
2025
Q1
$160K Hold
6,025
– – 0.01% 214
2024
Q4
$160K Buy
6,025
+152
+3% +$4.12K 0.01% 214
2024
Q3
$170K Sell
5,873
-1,052
-15% -$30.7K 0.01% 205
2024
Q2
$194K Buy
6,925
+480
+7% +$13.2K 0.02% 186
2024
Q1
$186K Hold
6,445
– – 0.02% 187
2023
Q4
$186K Sell
6,445
-1,190
-16% -$36K 0.02% 187
2023
Q3
$253K Buy
7,635
+463
+6% +$16.4K 0.03% 145
2023
Q2
$263K Sell
7,172
-1,075
-13% -$41.8K 0.03% 144
2023
Q1
$336K Sell
8,247
-508
-6% -$21.9K 0.04% 115
2022
Q4
$449K Buy
+8,755
New +$420K 0.06% 95

Other funds holding PFE

Armstrong Advisory Group's PFE Position: Q3 2026 in Review

Armstrong Advisory Group increased its Pfizer (PFE) stake by 0.4% in Q3 2026, buying an estimated $1.12K and bringing the position to 10,442 shares worth $298K. The position accounts for 0.02% of the portfolio, ranked #196.

Armstrong Advisory Group first reported a position in PFE in Q4 2022 and has held it in 16 quarters since. The position peaked at $449K in Q4 2022. 559 funds tracked by Wall St. Rank hold PFE as of Q3 2026.

  • Armstrong Advisory Group held 10,442 shares of Pfizer worth $298K as of Q3 2026.
  • Armstrong Advisory Group bought 42 Pfizer shares in Q3 2026, an estimated $1.12K.
  • Pfizer made up 0.02% of Armstrong Advisory Group's portfolio in Q3 2026, its #196 holding.
  • Armstrong Advisory Group first reported a position in Pfizer in Q4 2022 and has held it in 16 quarters since.
  • Armstrong Advisory Group's Pfizer position peaked at $449K in Q4 2022.
  • 559 funds tracked by Wall St. Rank held Pfizer as of Q3 2026.

Based on Armstrong Advisory Group's 13F filing for Q3 2026, filed 9 Oct 2026.